Our data raise the possibility that therapeutic intervention simultaneously targeting both PKCα and PKCε might have some therapeutic benefit to patients, although it will be an important next step to formally demonstrate that the function of these specific isoforms is broadly conserved in additional models of breast cancer. This evidence concerns the gene PRKCA and breast cancer.